
    
      Subjects will participate in the study for up to 168 days. Up to 20 subjects will be enrolled
      in the study.

      Subjects will self-administer study medication as subcutaneous (SC) injections in the abdomen
      (preferably) twice per day; the first dose each day should be administered in the morning and
      the evening dose should be administered within 8 to 16 hours after the morning dose.

      Safety assessments will be conducted at each study visit during treatment and AEs will be
      collected throughout the Treatment period and during the 56-days observation period visits.
    
  